Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LONDON STOCK EXCHANGE GROUP. We currently have 10 research reports from 3 professional analysts.
|28Mar17 15:20||RNS||Form 8.3 - London Stock Exchange Group PLC|
|28Mar17 15:03||RNS||Form 8.5 (EPT/RI)-London Stock Ex Gp Plc Amendment|
|28Mar17 14:37||RNS||Form 8.3 - London Stock Exchange Group Plc|
|28Mar17 14:33||RNS||Form 8.3 - Deutsche Boerse AG|
|28Mar17 14:04||RNS||Form 8.3 - London Stock Exchange Group Plc|
|28Mar17 13:33||RNS||Form 8.3 - Deutsche Boerse AG|
|28Mar17 13:30||RNS||Form 8.3 - London Stock Exchange Group Plc|
Frequency of research reports
Research reports on
LONDON STOCK EXCHANGE GROUP
LONDON STOCK EXCHANGE GROUP
Another year of strong growth
03 Mar 17
The London Stock Exchange Group (LSEG) released its FY2016 results this morning. This turned out to be quite strong, as total income at $1.66bn was 4% higher than expected by consensus and 5% higher than expectations. Total expenses were also 6% higher than expected. Adjusted operating profit (before amortisation and one-off items) was therefore in line with expectations at £690m. DPS is 20% higher yoy in line with earnings growth and 6% higher than consensus expectations.
Positive on revenues, higher than expected total expenses not an issue...
04 Aug 16
LSEG reported a good set of numbers, especially on revenues which, aside topping estimates by 3.5%, were up 7% yoy (on an organic and constant currency basis). Total expenses were, however, short of expectations with a 5.3% miss driven by higher employee costs. Operating profit was therefore in line with expectations and 5% higher yoy. No material information regarding the ongoing merger was released. Total operating profit was -9% yoy as exceptional transactions costs (linked to the sale of Russell investment) were incurred.
06 May 16
"Equities in London are expected to open on a downbeat note, with the FTSE-100 expected to fall initially around 15 points, before testing its technical support at the 6,100 level. After early strength, the US markets gave back gains made on the back of firm oil and energy prices as investors focussed back on a relatively dull earnings season, growing political uncertainty and lacklustre economic data. Recent strength in gold and bond markets serves as a reminder of investor's continuing concerns for the global economy. Key macroeconomic data due today from the US includes the monthly non-farm payroll employment report, which may determine both expectations for the Fed's interest rate policy and sentiment for the coming week. In the UK, markets await this morning's release on the Halifax house price index and AGMs from Alliance Trust, RSA Insurance and Man Group, together with trading statements from BBA Aviation and International Consolidated Airlines." - Barry Gibb, Research Analyst
Is this really the end? Not so sure...
04 May 16
ICE announced during its Q1 16 earnings release that it won’t be proceding with a bid on the LSEG as we had been expecting for weeks with a high probability. ICE justified the move as “following due diligence on the information made available, ICE determined that there was insufficient engagement to confirm the potential market and shareholder benefits of a strategic combination”. This is at first glance a courteous way to define LSEG’s management behaviour not to cooperate. As confirmed by ICE’s CEO, Jeffrey Sprecher, ICE’s board had tried and failed to arrange meetings with the LSEG. Following the announcement, the LSEG share dropped while the Deutsche Boerse share gained, coming back to pre ICE’s announcement level, respectively around 2600p and €75.5.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.